REFERENCES
- Ng CH, Schweitzer I, Norman T . The emerging role of pharmacogenetics: implications for clinical psychiatry. Australian and New Zealand Journal of Psychiatry 2004; 38: 483–489.
- Kirchheiner J, Brosen K, Dahl ML . CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatrica Scandinavica 2001; 104: 173–192.
- Solomon DA, Leon AC, Mueller TI . Tachyphylaxis in unipolar major depressive disorder. Journal of Clinical Psychiatry 2005; 66: 283–290.
- Sistonen J, Fuselli S, Levo A . CYP2D6 genotyping by a multiplex primer extension. Clinical Chemistry 2005; 51: 1291–1295.
- Fuselli S, Dupanloup I, Frigato E . Molecular diversity at the CYP2D6 locus in the mediterranean region. European Journal of Human Genetics 2004; 12: 916–924.
- De Leon J, Armstrong SC, Cozza K L. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006; 47: 75–85.